-
In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
Newcomb and colleagues reported breast cancer mortality in the Collaborative Breast Cancer Study Cohort, a prospective cohort of 12,269 postmenopausal women from Wisconsin, Massachusetts, or New Hampshire.
-
-
Estrogen treatment (but not estrogen given along with progestin) seems associated with gastro-esophageal reflux (GER) in postmenopausal women. Weight gain increases risk.
-
Clinical trials of pharmacotherapy to prevent progression of cognitive decline in those with mild cognitive impairment (MCI) have been disappointing; neither cholinesterase inhibitors (donepezil, rivastigmine, galantamine), vitamin E, nor COX-2 inhibitors has demonstrated any clinically meaningful benefit in placebo-controlled MCI trials.
-
The ECG shown above was obtained from a patient who was seen in the office with atypical chest pain. Is there cause for concern?
-
Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
In knee OA, arthroscopic surgery confers no benefit.
-
Whereas racial concordance is the primary predictor of perceived ethnic similarity, patients do value higher communication skills, which may actually result in better outcomes.
-
The FDA has approved the first drug for the treatment of Huntington's disease.
